Lindsey Trickett
Investor Relations Contact bij F-STAR THERAPEUTICS, INC.
Actieve functies van Lindsey Trickett
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| F-STAR THERAPEUTICS, INC. | Investor Relations Contact | - | - |
| Public Communications Contact | - | - | |
| PRELUDE THERAPEUTICS INCORPORATED | Investor Relations Contact | - | - |
Loopbaan van Lindsey Trickett
Eerdere bekende functies van Lindsey Trickett
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Investor Relations Contact | 07-09-2017 | - |
Opleiding van Lindsey Trickett
| University of Kentucky | Undergraduate Degree |
| Georgetown University | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 5 |
| Verenigd Koninkrijk | 2 |
Operationeel
| Investor Relations Contact | 3 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
F-star Therapeutics, Inc.
 F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Lindsey Trickett
- Ervaring
